佐力药业(300181) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 672,899,096.57, representing a year-on-year increase of 35.75% compared to CNY 495,697,829.83 in the same period last year[4]. - Net profit attributable to shareholders for Q1 2024 was CNY 142,415,333.77, up 46.14% from CNY 97,454,603.35 in the previous year[4]. - Basic earnings per share for Q1 2024 were CNY 0.2030, a 46.15% increase from CNY 0.1389 in the previous year[4]. - Total comprehensive income for Q1 2024 reached CNY 135,283,665.64, a significant increase from CNY 51,254,457.45 in Q1 2023, representing a growth of approximately 163.5%[25]. - Net profit for Q1 2024 was ¥144,106,493.76, representing a 45.0% increase from ¥99,453,357.42 in Q1 2023[24]. Cash Flow - The net cash flow from operating activities was CNY 17,067,450.04, reflecting a 42.07% increase from CNY 12,013,227.66 in the same period last year[4]. - The net cash inflow from operating activities was CNY 17.0675 million, an increase of CNY 5.0542 million or 42.07% year-on-year, primarily due to the increase in operating profit during the reporting period[12]. - Cash inflow from investment activities in Q1 2024 was CNY 150,653,826.11, a substantial increase from CNY 10,856,728.14 in Q1 2023, marking a growth of about 1,384.5%[28]. - Net cash flow from investment activities for Q1 2024 was CNY 74,160,686.49, a turnaround from a negative cash flow of CNY 64,248,767.61 in Q1 2023[28]. - Net cash outflow from financing activities for Q1 2024 was CNY 22,642,770.73, compared to a smaller outflow of CNY 1,328,711.43 in Q1 2023[28]. Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 3,864,648,627.05, a 6.55% increase from CNY 3,627,038,970.51 at the end of the previous year[4]. - Current liabilities totaled ¥901,185,580.04, an increase of 13.4% from ¥794,825,470.40 in the previous year[21]. - The company's total assets increased to ¥3,864,648,627.05, up from ¥3,627,038,970.51, reflecting a growth of 6.5%[21]. Revenue Sources - The revenue from the Wuling series increased by 35.30%, driven by a 43.86% rise in sales volume of Wuling capsules[10]. - The revenue from traditional Chinese medicine formula granules surged by 332.99% year-on-year, attributed to the increase in national and provincial standard filings[10]. - Other income for Q1 2024 was CNY 2,935.11 million, a 54.75% increase compared to the previous year, mainly due to increased government subsidies[10]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 36,904, with no preferred shareholders having restored voting rights[13]. - The largest shareholder, Yu Youqiang, holds 18.52% of the shares, amounting to 129,890,463 shares, with 90 million shares pledged[13]. Legal Matters - The company is involved in a patent infringement lawsuit with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., which has been accepted by the Zhejiang High Court[17]. Research and Development - Research and development expenses for Q1 2024 were ¥14,564,920.81, a decrease of 20.3% compared to ¥18,208,988.62 in Q1 2023[24].